The UK biotech gets a big boost from the sale of a pan-Raf inhibitor to Jazz Pharmaceuticals, but Redx’s money worries are far from over.
The second mega-merger in as many quarters means a huge M&A year is in the making, but a look at deal volume tells another story.
Probiodrug changes its name to Vivoryon and expands its focus to include oncology, but insists that it is still first and foremost an Alzheimer’s company.
Hopes for lumateperone rest on schizophrenia as bipolar data raise questions.
The medtech market’s fast growth and unfettered demand attracts investment groups, while hospital suppliers consolidate.
Sangamo is slowly building a case for SB-525 over Biomarin’s valrox.
Investor excitement about smaller medtechs’ technology is unchecked, but these groups will have to deliver on their promises.
The usual story of positive data and clinical failure influencing company stock performance was given added interest in the second quarter with price fixing allegations…
Newly-listed NGM Biopharmaceuticals needs its Nash project to impress in phase II, while Enanta must show that it also has a foot in the door in the liver disease.
Exact Sciences finds that where there’s muck there’s brass, but specialisation does not work as well for Abiomed.
Positive data, toxicity, a US FDA delay and the early leaking of information culminate in a green light for the multiple myeloma drug.
Yet another project brought in through business development fails, exposing Sumitomo’s limited pipeline.
Paying $40m up front for a preclinical asset is a bold move, even for the red-hot Nash space, though Boehringer has shelled out here before.
After a quiet first quarter demand for new issues has returned to levels seen in 2018, itself a record year for IPOs of young drug developers.
Competition is looming from Novartis and Roche but the latest results from Spinraza show that Biogen still has a strong case to make for the SMA therapy.
Indulging in M&A is not the way to bump up share prices as oncology-focused companies prove to be the sector’s darlings.
A delayed decision on Karyopharm’s selinexor is the pick of the bunch for July.
Worries over toxicity with Pfizer's PF-06939926 halts trial dosing and could leave the way clear for its DMD rival Sarepta.
Both Ardelyx and Rhythm Pharmaceuticals are looking for phase III clinical wins to kick off filing discussions for pipeline leads.